As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and the improved standards for heparin export pulled down the export volume of China's heparin API during 2011-2013. From 2014 onwards, China has seen the export of heparin and its salts warm up. From January to October of 2015, China exported 123.2 tons of heparin and its salts, higher than 106.7 tons in the whole 2014; however, the average export price fell 30.7% year on year to USD3,945.6 / ton.
The major global heparin API suppliers, including Hepalink, Nanjing King-friend, Dongcheng Biochemicals and Qianhong Bio-pharma generated the combined capacity of over 20 trillion units in 2014; also, they have been among the top 4 heparin exporters in China for many years, together accounting for over 70% of China’s total heparin exports.
Along with the intensified heparin API supply capacity and raised product grades, Chinese heparin preparation market size is constantly expanding, reaching about RMB5 billion in 2014. In April 2015, Ministry of Human Resources and Social Security of the People's Republic of China issued Circular on Adjusting and Standardizing Some Drugs Listed in Drug Catalog of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance to contain "enoxaparin sodium injection", "dalteparin sodium injection" and "nadroparin calcium injection" in the aforementioned catalog (previously only included in the medical insurance of some provinces and cities). This move will undoubtedly stimulate the consumption of heparin preparations in China, especially low molecular weight heparin preparations. Chinese heparin preparation market size is expected to jump 27.9% year on year to RMB6.38 billion in 2015.
Based on the corporate development and positive prospects of heparin products, Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma, Changshan Biochemical Pharmaceutical and other companies have been either deploying or improving low molecular weight heparin API and preparation industries in recent years.
Nanjing King-friend has consistently ranked second in Chinese heparin API export market in recent years, and boasts the most diversified low molecular weight heparin products. In 2014, the company produced and sold about 4 trillion units of heparin API. Meanwhile, it received new drug certifications on enoxaparin sodium API and preparations, dalteparin sodium API and preparations. It obtained an approval on nadroparin calcium API and preparations on May 13, 2015. In addition, Nanjing King-friend has a production line involved with 3000kg/a low molecular weight heparin (1000kg/a enoxaparin sodium, 1000kg/a dalteparin, 1000kg/a nadroparin calcium) under construction; the project is expected to be completed and put into operation in December 2017.
As one of the main suppliers of heparin API in China, Qianhong Bio-pharma has ranked fourth in exports in recent years. In 2014, the company's heparin API capacity amounted to 5.5 trillion units, but the annual output and sales volume only reached about 2 trillion units based on market considerations. In 2015, the company was granted with a drug registration approval on enoxaparin sodium API and preparations; its dalteparin passed the inspection by CFDA; its nadroparin API and preparations were recognized by new drug review in December, and will go into the production inspection stage. Besides, the company’s ongoing heparin sodium preparation expansion project is expected to be completed in March 2016.
China Heparin Industry Report, 2015-2018 mainly deals with the followings: Global heparin supply & demand, competitive landscape and forecast, etc.; Policies, market situation, competitive landscape, import & export, and development forecast, etc. of China heparin industry; Operation, Heparin Business, development prospect, etc. of 7 heparin enterprises in China.
Our reports have been used by over 10K customers, including:
The global cell dissociation market size is projected to reach USD 561 million by 2026 from USD 282 million in 2021, at a CAGR of 14.7% during the forecast period. The growth in this market is attributed to the prevalence of cell based research, the increasing number of pharmaceutical and biotechnology companies. Moreover, the growth opportunities...
This IDC Perspective illustrates how Debiopharm (a Swiss biopharmaceutical company) embarked on a digital transformation journey in which cybersecurity has become a top priority. This report highlights the key elements of this journey, including the adoption of artificial intelligence solutions to protect the intellectual property of its business...
Apoptosis Regulator BAX - Drugs In Development, 2021 Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2....
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Biosimilars Market 2021-2025 The analyst has been monitoring the biosimilars market and it is poised to grow by $ 31.40 bn during 2021-2025, progressing at a CAGR of 24.77% during the forecast period. Our report on the biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers,...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Bioreactors Market 2021-2025 The analyst has been monitoring the bioreactors market and it is poised to grow by $ 3.99 billion during 2021-2025, progressing at a CAGR of 15.61% during the forecast period. Our report on the bioreactors market provides a holistic analysis, market size and forecast, trends, growth drivers,...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
The biopharmaceutical tubing market is expected to reach US$ 6,013.27 million by 2028 from US$ 3,442.82 million in 2021; it is estimated to grow at a CAGR of 8.3% from 2021 to 2028. The factors increasing elderly population in world, and rising demand for minimally invasive procedures are contributing to the market growth. However, the stringent...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the vaccines market are AstraZeneca, Emergent Biosolutions, GlaxoSmithKline, Merck, and Pfizer Inc. The global vaccines market is expected to decline from $56.02 billion in 2020 to $55.97 billion in 2021 at a compound annual growth rate (CAGR) of -0.1%. The slow decline is mainly due to the outbreak of COVID-19 that...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.